Phenibut: Difference between revisions
Line 122: | Line 122: | ||
[[Category:GABA analogues]] |
[[Category:GABA analogues]] |
||
[[Category:GABAB receptor agonists]] |
[[Category:GABAB receptor agonists]] |
||
[[Category:Euphoriants]] |
|||
[[Category:Bodybuilding supplements]] |
[[Category:Bodybuilding supplements]] |
||
[[Category:Russian drugs]] |
[[Category:Russian drugs]] |
Revision as of 03:07, 25 January 2015
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Noofen |
Other names | Fenibut, Phenybut, PhGABA |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 5 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.012.800 |
Chemical and physical data | |
Formula | C10H13NO2 |
Molar mass | 179.216 g/mol g·mol−1 |
3D model (JSmol) | |
Melting point | 253 °C (487 °F) |
| |
| |
![]() ![]() |
Phenibut[note 1] (contracted from β-phenyl-γ-aminobutyric acid) is a central nervous system (CNS) depressant and derivative of the naturally occurring inhibitory neurotransmitter γ-aminobutyric acid (GABA). The addition of a phenyl ring allows phenibut to cross the blood brain barrier.[1] Phenibut is sold as a nutritional supplement,[2] and is not approved as a pharmaceutical in the United States or Europe, but in Russia it is sold as a psychotropic drug. It has been reported by some to possess nootropic actions for its ability to improve neurological functions,[3]
This article needs additional citations for verification. (January 2015) |
but other researchers have not observed these effects.[4] It is generally accepted that phenibut has anxiolytic effects in both animal models and in humans.[1] Phenibut was discovered in the Soviet Union in the 1960s, and has since been used there to treat a wide range of ailments including post-traumatic stress disorder, anxiety, and insomnia.[3]
The name phenibut, along with many of the other names for the compound, comes directly from the chemical name for the compound, β-phenyl-γ-aminobutyric acid.
History
Phenibut was synthesized at the I. M. Herzen Leningrad Pedagogical Institute USSR and the Institute of Experimental Medicine, Academy of Medical Sciences USSR by Professor V. V. Perekalin's team.
Phenibut is mandated standard equipment in a Russian cosmonaut's medical kit. The use of "conventional" tranquilizers for stress and anxiety makes patients drowsy, which was deemed unacceptable for cosmonauts; phenibut, however, lowers stress levels without adversely affecting performance.
This article needs additional citations for verification. (January 2015) |
In 1975 phenibut was included in the cosmonauts' kit for those who participated in the Apollo-Soyuz joint mission.[5]
General information
In chemical structure, phenibut is a phenyl derivative of GABA. Although the calming action is similar to other GABA agonists,
This article needs additional citations for verification. |
phenibut binds to the GABAB metabotropic receptor, the same site responsible for the sedative effects of baclofen (the para-chloro derivative of phenibut) and γ-hydroxybutyrate (GHB), although GHB also acts at the GHB receptor.[6] There is dispute in the literature about whether or not phenibut binds to the GABAA ionotropic receptor, which is responsible for the actions of the benzodiazepines, barbiturates, z-drugs, and for some of the effects of ethanol. According to Allikmets and Ryage (1983) and Shulgina (1986) phenibut does bind to the GABAA receptor,[3] but according to Lapin (2001) it does not.[1] In the case of the former, it is argued that the GABAA binding only occurs at higher concentrations.[3]
The literature that supports the nootropic effects of phenibut also suggest it elicits tranquilizing effects,[1] reduction of stress and anxiety, improvement of impaired sleep, and the potentiation of the effects of tranquilizers, narcotics, and neuroleptics. It is also suggested to have an anticonvulsant effect,[3] though studies on other GABAB agonists, such as GHB and the phenibut analogue baclofen, have shown them to act as potential convulsants.[citation needed] It should be noted, however, that GHB acts on the convulsion-inducing GHB receptor,[7] which phenibut does not.
Physical properties
Phenibut HCl is a white crystalline powder and the taste is very sour. It is readily soluble in water, soluble in alcohol, and the pH of a 2.5% water solution is between about 2.3 and 2.7.
Chemistry
Phenibut is a γ-aminobutyric acid with a phenyl group in the β-position. It is a chiral molecule and thus has two potential configurations, an (R)- and (S)-enantiomer. In phenibut, only the (R)-enantiomer is biologically active leaving the (S)-enantiomer of little value.[6] It has the same structure of baclofen[3] (lacking only a chlorine atom in the para-position of the phenyl group) and includes the phenylethylamine structure.
Pregabalin has instead the phenyl group substituted with the isobutyl group.
Pharmacology
The pharmacological effects of phenibut are similar to baclofen [citation needed], but less potent per milligram of dosage.
Phenibut exerts its effects by being an agonist at the metabotropic GABAB receptor, and at higher doses also at the ionotropic GABAA receptor.[3]
Some studies found that phenibut antagonizes the effects of phenethylamine (PEA),[1][8] while others found no effect on PEA-induced anxiety.[9]
Furthermore, phenibut has been shown to increase dopamine levels.[1]
Contraindications and side effects
Persons on MAO inhibitors or epilepsy medications like carbamazepine or oxcarbazepine should consult with their physician or pharmacist prior to supplementation with phenibut. Some evidence suggests that phenibut can modulate the function of some epilepsy medications.[3]
See also
References
- ^ a b c d e f Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 11830761 , please use {{cite journal}} with
|pmid= 11830761
instead. - ^ Nelson, LS (2008). "Phenibut Withdrawal - A Novel 'Nutritional Supplement'". Clinical Toxicology. 46 (7): 605.
- ^ a b c d e f g h Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 2431377 , please use {{cite journal}} with
|pmid= 2431377
instead. - ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 6705902 , please use {{cite journal}} with
|pmid= 6705902
instead. - ^ Slava Lapin (30 July 2009). From the Inside. Luniver Press. p. 209. ISBN 978-1-905986-11-8. Retrieved 6 November 2010.
- ^ a b Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 18275958 , please use {{cite journal}} with
|pmid= 18275958
instead. - ^
Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 7791129 , please use {{cite journal}} with
|pmid= 7791129
instead. - ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 4043364 , please use {{cite journal}} with
|pmid= 4043364
instead. - ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 1804703 , please use {{cite journal}} with
|pmid= 1804703
instead.
Notes
- ^ Synonyms and alternate spellings include: fenibut, phenybut and Noofen.
External links